73 related articles for article (PubMed ID: 22042416)
1. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.
Mamtani R; Clark AS; Scott FI; Brensinger CM; Boursi B; Chen L; Xie F; Yun H; Osterman MT; Curtis JR; Lewis JD
Arthritis Rheumatol; 2016 Oct; 68(10):2403-11. PubMed ID: 27159030
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression, IBD, and risk of lymphoma.
Bebb JR; Aithal GP; Logan RP
Gut; 2002 Aug; 51(2):296. PubMed ID: 12117900
[No Abstract] [Full Text] [Related]
3. The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review.
Stasik K; Filip R
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673824
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Antibiotics and risk of IBD-Can we close the books?
Ebrahimi F; Forss A
Aliment Pharmacol Ther; 2023 Jul; 58(2):254-255. PubMed ID: 37352156
[No Abstract] [Full Text] [Related]
5. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.
Sokol H; Beaugerie L
Gut; 2009 Oct; 58(10):1427-36. PubMed ID: 19749141
[TBL] [Abstract][Full Text] [Related]
6. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
7. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
8. [Inflammatory bowel disease and lymphoproliferative disorders].
Ye BD
Korean J Gastroenterol; 2011 Oct; 58(4):171-7. PubMed ID: 22042416
[TBL] [Abstract][Full Text] [Related]
9. Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype.
Satou A; Tsuzuki T; Nakamura S
J Clin Exp Hematop; 2019; 59(2):56-63. PubMed ID: 31257346
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
Subramaniam K; D'Rozario J; Pavli P
J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]